Skip to NavigationSkip to content

Samsung beats pharma to develop first EU-approved Enbrel biosimilar

Published on 18/01/16 at 05:10pm
Samsung Bioepis
Engineers at the Samsung Bioepis R&D Centre (Photo: Business Wire)

Samsung Bioepis – the collaboration between Samsung Biologics and Biogen Idec, has become the first company to have a biosimilar version of Enbrel approved by the EMA.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, meaning a European Commission (EC) approval for Benepali, a copycat version of Enbrel (etanercept) is likely.

It is recommended for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque psoriasis, and marks the first time the CHMP has adopted a positive opinion on an etanercept biosimilar. If a marketing authorisation is granted by the EC, Benepali will be the first etanercept biosimilar to be approved in the European Union.

To earn the positive opinion, Samsung Bioepis had to demonstrate that the biosimilar has the same chemical quality, efficacy and safety as the reference product. In November, positive results from a one-year Phase III study, presented at the American College of Rheumatology conference its version of etanercept sustained comparable safety profiles.

The 52-week SB4 study, which randomised 596 patients in 10 countries, showed a 20% improvement (ACR20 response) rate of 80.8% in patients who took the biosimilar, compared to 81.5% in the Enbrel arm. An earlier analysis of results after 24-week study results found rates of 78.1% and 80.3%, respectively.

“The approval of Benepali and its subsequent launches in Europe are major milestones for Samsung Bioepis,” said Christopher Hansung Ko, president and chief executive of Samsung Bioepis. “In just under four years, we successfully developed, tested and obtained regulatory approval for Benepali, a high-quality biologic medicine that will drive down healthcare costs and increase patient access to one of the most widely used treatment options for immunological diseases across Europe.”

In addition to Benepali, Samsung Bioepis has been developing two other anti-tumour necrosis factor-alpha (anti-TNF-alpha) investigational biosimilar candidates: SB2 investigational biosimilar candidate to Remicade (infliximab), and SB5 investigational biosimilar candidate to Humira (adalimumab).

Lilian Anekwe

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches